Compare FuelCell Energy Inc (FCEL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Incyte Corporation — how do they compare? FuelCell Energy Inc trades at $17.66 (market cap $1.47B), while Incyte Corporation trades at $112.75 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 15.5× FuelCell Energy Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Incyte Corporation for 33 Days on average.
| FCEL | INCY | |
|---|---|---|
Market Cap | $1.47B | $22.85B |
Volume | 12,559,948 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $36.01 | $129.93 |
52-Week Low | $6.00 | $83.80 |
Typical Hold Time | 48 Days | 33 Days |
Enterprise Value | $1.05B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCEL stock trades at $18.37, down 11.07% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $158.16M in 2025 but sustained a net loss of $187.90M, reflecting negative profit margins. Recent news highlights a securities class action lawsuit filed against the company, alleging disclosure failures between June and September 2026.
The outlook remains challenged by persistent losses and high cash burn, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Key risks include the class action litigation, execution on profitability, and reliance on financing activities to fund operations.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
